Mega Genomics Limited (HKG:6667)

Market Cap	1.60B -0.9%
Revenue (ttm)	413.73M +159.3%
Net Income	28.30M -30.6%
EPS	0.14 -25.0%
Shares Out	223.19M
PE Ratio	50.03
Forward PE	n/a
Dividend	0.18 (2.44%)
Ex-Dividend Date	May 26, 2026

Volume	49,800
Open	7.12
Previous Close	7.12
Day's Range	7.12 - 7.20
52-Week Range	5.00 - 7.53
Beta	0.76
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About Mega Genomics

Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing; cardiovascular and cerebrovascul...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Employees: 196
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6667

Financial Performance

In 2025, Mega Genomics's revenue was 247.15 million, an increase of 50.49% compared to the previous year's 164.23 million. Earnings were 27.02 million, a decrease of -40.01%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error